You have accessJournal of UrologySexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy I1 Apr 2018PD31-09 PRE-BIOPSY HYPOGONADISM IN PROSTATE CANCER PATIENTS IS ASSOCIATED WITH METASTATIC PROSTATE CANCER IN THE VETERAN POPULATION Alan Hsieh, Lorenzo DiGiorgio, Sri Pentakota, Chrystal Chang, and Hossein Sadeghi-Nejad Alan HsiehAlan Hsieh More articles by this author , Lorenzo DiGiorgioLorenzo DiGiorgio More articles by this author , Sri PentakotaSri Pentakota More articles by this author , Chrystal ChangChrystal Chang More articles by this author , and Hossein Sadeghi-NejadHossein Sadeghi-Nejad More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.1540AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Recent studies have demonstrated that compared to eugonadal men, lower testosterone levels are associated with higher rates of prostate cancer, as well as more aggressive disease with higher tumor volume, grade, and stage. This study was conducted with the aim of identifying possible associations between endogenous testosterone levels and prostate cancer aggressiveness in the veteran population. METHODS Following IRB approval at the local Veterans Affairs Medical Center, a retrospective chart review of all patients diagnosed with prostate cancer for the first time between 1/2010 and 1/2016 was performed. Electronic medical records were used to identify patients with testosterone levels measured within 6 months of prostate biopsy. Patient demographic information including age and ethnicity were collected. Prostate cancer parameters such as serum PSA, total testosterone level, Gleason score, and clinical staging were also assessed. Low testosterone was defined as <300 ng/dL. The presence of metastatic disease was clinically evaluated using bone scan and CT scan. RESULTS Of the 200 patients who were diagnosed with prostate cancer for the first time and had a total testosterone measured within 6 months of diagnosis, 109 (54.5%) had low testosterone and forty-one (20.5%) had metastatic disease upon presentation. The men in the low testosterone group were older (68.6 vs 65.4 years, p=0.006) and more likely to be diagnosed with metastatic disease (28.4% vs 11.0%, p<0.001) than the group with normal testosterone levels. However, on multivariate logistic regression analysis, low testosterone was not significantly associated with metastases (OR: 2.513, CI: 0.875-7.221), while Gleason score 8+ and higher PSA were identified as independent risk factors. CONCLUSIONS In this small, retrospective study, patients with low testosterone were more likely to be diagnosed with disease. Although not quite statistically significant, the association between low testosterone and metastatic disease suggests that clinicians may need to be more vigilant with a higher index of suspicion for metastatic disease in hypogonadal men diagnosed with prostate cancer. Larger, prospective studies are needed to corroborate these findings. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e643 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Alan Hsieh More articles by this author Lorenzo DiGiorgio More articles by this author Sri Pentakota More articles by this author Chrystal Chang More articles by this author Hossein Sadeghi-Nejad More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...